Skip to main content

Table 4 Summary of adverse events by type and study period.

From: A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)

SOC Preferred Term Adverse Events 4-Weeks (n) (%)a Adverse Events Follow up (n) (%)b
Patients 64   60  
Patients who Experienced Adverse Events 32 50.0 16 26.6
Palpitations 4 6.3 0 0
Abdominal Pain Upper 3 4.7 3 4.9
Diarrhea 4 6.3 2 3.3
Dyspepsia 7 10.9 0 0
Gastrointestinal Pain 10 15.6 3 4.9
Nausea 13 20.3 8 13.1
Vomiting 7 10.9 2 3.3
Asthenia 2 3.1 2 3.3
Fatigue 8 12.5 9 14.8
Pain 4 6.3 0 0
Headache 8 12.5 6 9.8
Tremor 4 6.3 1 1.6
Insomnia 4 6.3 2 3.3
Irritability 1 1.6 3 4.9
Hyperhidrosis 8 12.5 3 4.9
Rash 2 3.1 2 3.3
  1. a: Percentage based on all 64 patients. b: Percentage based on the 60 patients who were treated with Suboxone during the follow-up period.